Advanced Enzyme Technologies Announces Q1 Results, Share Buyback, and Subsidiary Stake Acquisition

Advanced Enzyme Technologies has reported its financial results for the quarter ended June 30, 2026, alongside key corporate actions including a share buyback and the acquisition of a remaining stake in a subsidiary.

What just happened

For the quarter ended June 30, 2026, Advanced Enzyme Technologies reported consolidated revenue from operations of ₹189.79 crore and a net profit of ₹38.59 crore. Basic Earnings Per Share (EPS) stood at ₹3.31.

In parallel, the company's Board approved a share buyback program through the open market route. The maximum buyback size is set at ₹69.70 crore, with a maximum price of ₹500 per share. This buyback will cover up to 1,394,000 shares, representing 1.24% of the company's existing paid-up capital.

Additionally, the company approved the acquisition of the remaining 4.28% stake in its subsidiary, JC Biotech Private Limited (JCB), for ₹7.98 crore. This move will make JCB a wholly-owned subsidiary.
A fund infusion of up to ₹2.00 crore into another wholly-owned subsidiary, Advanced Nutrazyme Private Limited (ANPL), was also approved.

Why this matters

These announcements signal a proactive approach by Advanced Enzyme Technologies in managing its capital and consolidating its business structure. The buyback can potentially boost shareholder value by reducing the equity base. The full acquisition of JC Biotech aims to streamline operations and unlock further synergies, potentially leading to improved profitability and efficiency in the long run.

The backstory

Advanced Enzyme Technologies is a global enzyme company that develops, manufactures, and supplies a wide range of enzyme solutions. JC Biotech is involved in a related business, and its full integration is a strategic step for the parent company.

What changes now

The acquisition will make JC Biotech a wholly-owned subsidiary, simplifying its ownership structure and facilitating better integration with the group's operations. The buyback program will commence as per SEBI regulations, impacting the company's cash reserves and share count.

Risks to watch

Execution risk in the share buyback and integration challenges with JC Biotech could impact the expected benefits. Market volatility could also affect the buyback price and overall financial performance.

Context metrics (time-bound)

Q1 FY27 Financials:

• Consolidated Revenue: ₹189.79 crore
• Consolidated Net Profit: ₹38.59 crore
• Basic EPS: ₹3.31

Share Buyback:

• Maximum Size: ₹69.70 crore
• Maximum Price: ₹500 per share
• Indicative Shares: 1,394,000 (1.24% of capital)

JC Biotech Acquisition:

• Remaining Stake: 4.28%
• Consideration: ₹7.98 crore

ANPL Fund Infusion:

• Maximum: ₹2.00 crore

What to track next

Investors will be watching the progress of the share buyback, the successful integration of JC Biotech, and the impact of these actions on future financial results. The company's ability to leverage synergies from the subsidiary acquisition will be a key focus.